Lunit, VIDI Bring AI Mammography to France's Largest Radiology Network

Lunit, a leader in AI-powered cancer diagnostic solutions, has formed a strategic partnership with VIDI Group, the largest private radiology and radiotherapy network in France. This collaboration will expand the use of Lunit INSIGHT MMG, an AI-driven solution for breast cancer screening, across VIDI’s network of over 400 sites and 1,200 doctors.

Lunit INSIGHT MMG helps radiologists detect breast cancer earlier and more accurately by analyzing mammography images to identify suspicious lesions and providing crucial information to assist in diagnosis.

This partnership offers several benefits:

• Enhanced Screening Efficiency: The AI solution streamlines breast cancer screening, improving efficiency and potentially reducing the need for additional imaging or biopsies.

• Improved Diagnostic Accuracy: By identifying subtle abnormalities, Lunit INSIGHT MMG helps radiologists detect cancer earlier, leading to better patient outcomes.

• Increased Access to AI Technology: The partnership extends Lunit’s AI technology across a significant portion of the French private radiology market.

• Commitment to Innovation: VIDI’s adoption of this technology reflects its dedication to integrating advanced solutions to enhance patient care.

• Lunit aims to strengthen its position in the French market through this partnership and explore broader opportunities with VIDI in education, communication, and product development.

Brandon Suh, CEO of Lunit, emphasized the importance of AI in early detection, noting, “With over 60,000 new cases of breast cancer in France in 2023, the need for AI support in early detection has never been greater. We believe that Lunit INSIGHT MMG will be an essential tool in the fight against breast cancer, helping radiologists detect what might otherwise be missed and ultimately saving more lives.”

Click here to read the original news story.